We demonstrated the efficacy of LiSmore in vivo by showing light-triggered TBK1 and IRF3 phosphorylation in LiSmore-engineered bone marrow-derived dendritic cells (BMDCs) within the tumor-draining lymph nodes (tdLNs) of B16 melanoma-bearing mice. This evidence concerns the gene IRF3 and melanoma.